Royal Free London NHS. NHS Foundation Trust. Bunis Packham
|
|
- Sherilyn Dawson
- 7 years ago
- Views:
Transcription
1 Royal Free London NHS. NHS Foundation Trust Bunis Packham Nurse Consultant Thrombosis & Anticoagulation Royal Free London Hospital NHS Foundation Trust Improving Adherence in patients on DOAC
2 Aim of the session Quiz NICE guidance NOAC referral process NOAC service Audit data Case scenarios Questions
3
4
5
6 Royal Free London NHS. NHS Foundation Trust How we got there Undertaking a medication history and successfully reconciling medicines Involving patients in decisions about prescribed medicines and supporting adherence: Implementing NICE, NPSA & NPC guidance The benefits of medicines reconciliation on patient outcomes Improving medicines management practice at discharge from hospital Patient views on non medical prescribing/pgd cost effectiveness
7 Aim of Service Achieve and maintain safety and effectiveness Increase patient adherence and attendance to follow up appointments, Reduce over and under anticoagulation and prolong associated hospital stay Provide a comprehensive and individualised patient care Ensure continuity and improve communication, information and education for patients, relatives, carers and primary health care
8
9
10 An estimated 50% of medicines for chronic Conditions are not taken as prescribed Ill-health and reduced quality of life Reduced life expectancy Avoidable healthcare cost Economic loss to society
11 QUIZ 1. What is the most serious side effect of NOACs? a) GI b) rashes c)bleeding d) renal failure 2. What is the half life of the NOACs in normal renal function? a) 12h b) 24h c) 36h d) 48h 3. What percentage of patients stop NOACs due to side effects? a) 5% b) 10% c) 20% d) 50% 4. The dose of Dabigatran must be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight
12 Quiz 5.The dose of Rivaroxabanmust be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight 6. The dose of Apixaban must be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight
13 NICE guidelines [CG180] Published date: June 2014 Interventions to prevent stroke Anticoagulation may be with apixaban, dabigatran etexilate, rivaroxaban or a vitamin K antagonist. Offer anticoagulation to people with a CHA2DS2VASc score of 2 or above, taking bleeding risk into account. [new 2014]
14 NICE guidelines [CG180] Published date: June 2014 Atrial fibrillation: the management of atrial fibrillation Treatment and care should take into account individual needs and preferences Patients should have the opportunity to make informed decisions about their care and treatment, in partnership with their healthcare professionals
15 Pharmacology Dabigatran 1-3 Rivaroxaban 4,5 Apixaban 6,7 Mode of action Factor II Factor X Factor X Half life hrs 7-11 hrs 12 hrs Metabolism Excretion Esterase catalysed hydrolysis 80% Renal CYP P450 dependant and independent mechanisms 1/3 Renal 2/3 Hepatic Form Capsule Tablet CYP P450 1/4 Renal 3/4 Non Renal Tablet Dosing in AF DVT/PE B.D. LMWH 7 days BD dose O.D. 15mg BD dose 21 days 20mg once a day B.D. 10mg BD dose 5 days 5mg BD dose Dose B.D. = twice daily; O.D. = once daily 150 mg 110 mg (>80 yrs, verapamil or increased bleeding risk) 20 mg 15 mg (CrCL ml/min) 5 mg 2.5 mg (2 or more: >80yr; weight <60 kg; Cr >1.5 mg/dl) Clinical Trial Data for information only - no clinical conclusions should be drawn. Please refer to individual product SPCs for further information. 1. Ezekowitz MD et al. Am Heart J 2009;157:805 10; 2. Connolly SJ et al. N Engl J Med 2009;361: ; 3. Connolly SJ et al. N Engl J Med 2010;363: ; 4. Rocket Investigators. Am Heart J 2010;159: ; 5. Patel MR et al. NEJM 2011;365:883 91; 6. Lopes et al. Am Heart J 2010;159:331-9; 7. Granger et al. N Eng J Med 2011;365:
16 Pharmacology TTR: 64% RE-LY 55% ROCKET AF 62% ARISTOTLE Dabigatran 1-3 Rivaroxaban 4,5 Apixaban 6,7 Factor II Factor X Factor X IschaemicStroke Prevention vs warfarin Superior@ 150mg 110mg Non-inferior (ITT analysis) Non-inferior Bleeding risk V warfarin 110mg GI 150mg ICH Generally sameas warfarin GI bleeding ICH bleeding No GI bleeding ICH Dosing B.D. O.D. B.D.
17 Doses for AF (see SPC for full dosing and prescribing information) Dabigatran 150 mg BD 110 mg BD e.g. if high risk of bleeds, CrCl ml/min, over 75 & considered a moderate risk of a bleed, over 80, very low body weight Do not add to Dosette box Ideally after food Interactions Potential for P-gp interactions, e.g. amiodarone, verapamil, quinidine, ketoconazole, clarithromycin, rifampicin, phenytoin and carbamazepine SSRIs and SNRIs increased the risk of bleeding in RE-LY in all treatment groups Concomitant treatment with systemic and ketoconazole, cyclosporine, itraconazole, tacrolimus and dronedarone is contraindicated 5
18 Rivaroxaban Rivaroxaban Interaction 20 mg OD If CrCl ml/min 15 mg OD Must taken with or after food Caution with strong CYP3A4 inducers e.g. rifampicin, phenytoin, carbamazepine Avoid concomitant treatment with strong inhibitors of both CYP3A4 and P-gp e.g. ketoconazole, itraconazole, voriconazole or HIV protease inhibitors
19 Apixaban Apixaban Interactions 5 mg BD All patients with creatinine clearance 15-29ml/min should receive 2.5 mg twice daily of Apixaban. In addition if they meet two of the following criteria they should receive the lower dose: serum creatinine 133 micromol/l, age 80years or body weight 60kg Avoid concomitant use with strong inhibitors of both CYP3A4 and P- gp e.g. ketoconazole, itraconazole, voriconazole or HIV protease inhibitors Caution with strong CYP3A4 inducers e.g. rifampicin, phenytoin, carbamazepine, phenobarbital or St. John s Wort as they may lead to reduced Apixaban concentrations 6
20 NOAC clinic referral process Anticoagulation clinic accepts referral from within the organisation, GPS and external organisation EPR referral not on warfarin referral EPR letter referral
21 Referral requirement Patient should have base line of HB, LFT and creatinine levels at least within the last month If the patient has been commenced on the NOAC already please give the patient blood request form. Ask patient to organise the blood test to be done a week before they attend the NOAC clinic
22 Royal Free London NHS. NHS Foundation Trust Involving patients in decisions about prescribed medicines Communication skills central Patient involvement patients differ in how much involvement they want Patient perspective is different from professional perspective Information patients cannot decide on involvement and decision unless they have information
23 Royal Free London NHS. NHS Foundation Trust Perspective of guideline Patient s right to be involved in decisions about their care Patient s right not to take medicines Medicine-taking is a complex behaviour Patient s act according to their own understanding of their problem and the medicine, and the place of this problem in their lives. Dynamic process ongoing evaluation and decisions by patient
24 Royal Free London NHS. NHS Foundation Trust Increasing patient involvement Clearly explain the condition and the pros and cons of treatment.what does this treatment do? Clarify what the patient hopes the treatment will achieve Talk and listen to the patient and note any non-verbal cues rather than make assumptions about patients preferences about treatment Help patients to make decisions based on likely benefits and risks rather than misconceptions.
25 Stroke risk assessment with CHA2DS2-VASc CHA2DS2-VASc criteria Score Congestive heart failure/ left ventricular dysfunction 1 Hypertension 1 Age 75 yrs 2 Diabetes mellitus 1 Stroke/transient ischaemic attack/te 2 Vascular disease (prior myocardial infarction, peripheral artery disease or aortic plaque) 1 Age yrs 1 Sex category (i.e. female gender) 1 CHA2DS2-VASc total score Rate of stroke/other TE (%/year)* * Theoretical rates without therapy: assuming that warfarin provides a 64% relative reduction in (2.7% ARR), based on Hart et al. TE = thromboembolism 1 Lip GYH et al. Stroke 2010;41: Hart RG et al. Ann Intern Med 2007;146: TE risk
26 Foundation For the Service Adopting a safety culture Trained, competent professionals, supervised until competency is achieved Implementing policies, protocols, guidelines Auditing the process, investigating any adverse events and quickly learning from mistakes Revising guidelines and protocols in order to achieve safety and gold standards
27 Aim ;Quality must be seen from patient s perspective Access to service Working in partnership Right to be involved in the decision making process Patient s right not to take the medication Ongoing support via telephone support line Dynamic process
28 Medication History What is the relevance of medication history in patients on anticoagulation therapy? What does medication history inform the anticoagulation nurse?
29 Case scenario 1 86 year old gentleman diagnosed with PE and DVT Dementia, wife is the main carer and she has MS Not able to manage LMWH require D/N Cr 77 weight 74 crcl 64 Last HB:14 Patient is on Phenytoin
30 Case Scenario 2 88 year old female Reason for A/C: Atrial Fibrillation CHA2DS2VASc score 4 ( age sex htn) Has bled 1 age Stroke risk 8.5% Recent result: Cr 69 weight 57 CrCl 50mL/min HB: 14 Which NOAC and why?
31 Pharmacology Dabigatran 1-3 Rivaroxaban 4,5 Apixaban 6,7 Mode of action Factor II Factor X Factor X Half life hrs 7-11 hrs 12 hrs Metabolism Excretion Esterase catalysed hydrolysis 80% Renal CYP P450 dependant and independent mechanisms 1/3 Renal 2/3 Hepatic Form Capsule Tablet CYP P450 1/4 Renal 3/4 Non Renal Tablet Dosing in AF DVT/PE B.D. LMWH 5 days BD dose O.D. 15mg BD dose 21 days 20mg once a day B.D. 10mg BD dose 5 days 5mg BD dose Dose 150 mg 110 mg (>80 yrs, verapamil or increased bleeding risk) B.D. = twice daily; O.D. = once daily 20 mg 15 mg (CrCL ml/min) 5 mg 2.5 mg (2 or more: >80yr; weight <60 kg; Cr >1.5 mg/dl) Clinical Trial Data for information only - no clinical conclusions should be drawn. Please refer to individual product SPCs for further information. 1. Ezekowitz MD et al. Am Heart J 2009;157:805 10; 2. Connolly SJ et al. N Engl J Med 2009;361: ; 3. Connolly SJ et al. N Engl J Med 2010;363: ; 4. Rocket Investigators. Am Heart J 2010;159: ; 5. Patel MR et al. NEJM 2011;365:883 91; 6. Lopes et al. Am Heart J 2010;159:331-9; 7. Granger et al. N Eng J Med 2011;365:
32 Case scenario 2 84 year old female Reason for A/C: Atrial Fibrillation CHA2DS2VASc score 6 ( stroke age sex htn) Has bled 2 age & stroke Discharged on Rivaroxaban 20mg Seen in anticoagulation clinic about 3 weeks later Cr 87 weight 48kg, CrCl 33 ml/min
33 Case Scenario 3 81 year old female Reason for A/C: Atrial Fibrillation CHA2DS2VASc score 6 ( age stroke, htn, sex) HAS BLED 3 ( age stroke INR) Has been commenced on warfarin very unstable. TTR of 56% Weight 52kg Cr 113 Cockcroft Gault 28mL/min What do we do?
34 Pharmacology Dabigatran 1-3 Rivaroxaban 4,5 Apixaban 6,7 Mode of action Factor II Factor X Factor X Half life hrs 7-11 hrs 12 hrs Metabolism Excretion Esterase catalysed hydrolysis 80% Renal CYP P450 dependant and independent mechanisms 1/3 Renal 2/3 Hepatic Form Capsule Tablet CYP P450 1/4 Renal 3/4 Non Renal Tablet Dosing in AF DVT/PE B.D. LMWH 7 days BD dose O.D. 15mg BD dose 21 days 20mg once a day B.D. 10mg BD dose 5 days 5mg BD dose Dose 150 mg 110 mg (>80 yrs, verapamil or increased bleeding risk) B.D. = twice daily; O.D. = once daily 20 mg 15 mg (CrCL ml/min) 5 mg 2.5 mg (2 or more: >80yr; weight <60 kg; Cr >1.5 mg/dl) Clinical Trial Data for information only - no clinical conclusions should be drawn. Please refer to individual product SPCs for further information. 1. Ezekowitz MD et al. Am Heart J 2009;157:805 10; 2. Connolly SJ et al. N Engl J Med 2009;361: ; 3. Connolly SJ et al. N Engl J Med 2010;363: ; 4. Rocket Investigators. Am Heart J 2010;159: ; 5. Patel MR et al. NEJM 2011;365:883 91; 6. Lopes et al. Am Heart J 2010;159:331-9; 7. Granger et al. N Eng J Med 2011;365:
35 Patients Numbers on NOAC (July June 2015)
36 NOAC: Dose Variation (July June 2015)
37 NOAC Use in Elderly Population
38 NOAC: Side Effects
39 NOAC: Gender
40 QUIZ 1. What is the most serious side effect of NOACs? a) GI b) rashes c)bleeding d) renal failure 2. What is the half life of the NOACs in normal renal function? a) 12h b) 24h c) 36h d) 48h 3. What percentage of patients stop NOACs due to side effects? a) 5% b) 10% c) 20% d) 50% 4. The dose of dabigatran must be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight
41 Quiz 5.The dose of Rivaroxaban must be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight 6. The dose of Apixaban must be appropriate for which of the following: a) RF b) LFTs c) Sex d) Age e) weight
42 References Department of Health. Pharmacy in England, building on strengths - delivering the future Friedman and Marr (1995) A supervisory model of professional competence: A joint service/education initiative Horne R 2006 Compliance, adherence and concordance implications for asthma treatment. Chest 130(1 Suppl)65S-72S Improving Patients Access to Medicines: A Guide to Implementing Nurse and Pharmacist Independent Prescribing within the NHS in England-2006 info@patientsafetyfirst.nhs.uk NICE 2009 Medicines Adherence: involving patients in decisions about prescribed medicines and supporting adherence NICE 2015 Medicine Optimisation NPSA Alert Anticoagulation World Health Organization. Adherence to long-term therapies; evidence for action WHO
Dorset Cardiac Centre
P a g e 1 Dorset Cardiac Centre Patients with Atrial Fibrillation/Flutter undergoing DC Cardioversion or Ablation procedures- Guidelines for Novel Oral Anti-coagulants (NOACS) licensed for this use February
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationAF, Stroke Risk and New Anticoagulants
Carmarthen Cardiac Update Course AF, Stroke Risk and New Anticoagulants Dr Hamsaraj Shetty, B.Sc, FRCP (London & Edinburgh) Consultant Physician & Honorary Senior Lecturer University Hospital of Wales,Cardiff
More informationNovel OAC s : How should we use them?
Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationAnticoagulation - which patients should be on Novel Oral Anticoagulants (NOAC)?
Anticoagulation - which patients should be on Novel Oral Anticoagulants (NOAC)? Welsh Primary Cardiovascular Conference Abertawe, Mai 2014 Gethin Ellis Cardiologist Cwm Taf UHB Declaration (?conflicts)
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationHow To Use Novel Anticoagulants In Cornwall
PENINSULA NETWORK GUIDANCE ON NOVEL ANTICOAGULANTS FOR STROKE AND TIA MANAGEMENT 1. Aim/Purpose of this Guideline The aim of this document to guide clinicians on use of novel anticoagulants for stroke
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More information22-Oct-14. Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants. Atrial Fibrillation. AF as an embolic risk factor
Oral Anticoagulation Which Drug for Which Patient in the era of New Oral Anti-coagulants Dr Scott McKenzie BSc MBBS FRACP FCSANZ Cardiologist, Vascular Physician, Telehealth Specialist, Advanced Heart
More informationNOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationNORTH WEST LONDON GUIDANCE ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION
North West London CardioVascular & Stroke Network NORTH WEST LONDON GUIDANCE ON ANTITHROMBOTIC MANAGEMENT OF ATRIAL FIBRILLATION Key Messages 1. Efforts should be made to identify patients with Atrial
More informationVOLUME No: 21 04 written by Sara Wilds & Kathryn Buchanan. Date of issue: June 2012 (updated November 2012 following NICE TA 256)
Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE PCT, JUBILEE HOUSE, OXFORD BUSINESS PARK SOUTH, OXFORD, OX4 2LH.
More informationAtrial fibrillation: medicines to help reduce your risk of a stroke what are the options?
Patient decision aid Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options? http://guidance.nice.org.uk/cg180/patientdecisionaid/pdf/english Published: June 2014 About
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationNovel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers
Novel Oral Anticoagulants and Warfarin Comparative evidence and Information for Prescribers How does it work? Dose and Administration Monitoring Warfarin Dabigatran Rivaroxaban Apixaban Warfarin has an
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More informationBreakfast symposium: From hospital to home - the focus on the patient
Breakfast symposium: From hospital to home - the focus on the patient Nadya Hamedi DARZI Fellow UCLPartners and Barts Health NHS Trust in collaboration with North Central London Local Pharmaceutical Committee
More informationΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν
ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationBirmingham, Sandwell and Solihull Cardiac and Stroke Network. Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement
Birmingham, Sandwell and Solihull Cardiac and Stroke Network Rivaroxaban or warfarin for treatment of Atrial Fibrillation: Position statement Introduction This guidance informs prescribers and commissioners
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationNHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
Version 3 August 2014 NHS DORSET CLINICAL COMMISSIONING GROUP POSITION STATEMENT ON ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION Dorset CCG commissions the use of newer oral anti-coagulants in accordance
More informationKevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013
Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationNew Anticoagulants. Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting. 30-Oct-14
Stroke Prevention in AF Commencing Novel Oral Anticoagulants (NOACs) in the GP Setting A/Prof Michael Nguyen Fremantle Hospital Access Cardiology General Practice Education Day Oct 2014 ORAL TTP889 Rivaroxaban
More informationTranslating clinical evidence into real-world outcomes
Annual Swiss Stroke Society Meeting 31st of January 2013 Symposium: From RE-LY to practice: Changing the attitude on stroke prevention in AF Translating clinical evidence into real-world outcomes Unité
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationNIL. Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts. Approach. Approach. 06-Nov-14
Stroke Prevention in Atrial Fibrillation: Commencing Non- Oral Anticoagulants in GP setting Dr Chuks Ajaero FMCP FRACP Cardiologist QEH, NALHN, SA Heart & Central Districts Disclosures NIL Classification
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationHow To Compare Warfarin To Dabigatran
Page 1 WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation WOMEN AT RISK Anticoagulation Issues In Atrial Fibrillation J E A N N A P P I, P H A R M. D., F C C P, B C P S Accreditation: Pharmacists:
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationDisclosures. Objectives 4/25/2014. Novel Anticoagulants in the Elderly
Novel Anticoagulants in the Elderly Bahar Matusik, PharmD, BCPS Assistant Professor Department of Pharmacy Practice & Administration University of Saint Joseph, School of Pharmacy Disclosures Dr. Bahar
More informationCardiovascular Subcommittee of PTAC Meeting held 27 February 2014. (minutes for web publishing)
Cardiovascular Subcommittee of PTAC Meeting held 27 February 2014 (minutes for web publishing) Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationPrevention of stroke in patients with atrial fibrillation
www.sign.ac.uk Prevention of stroke in patients with atrial fibrillation A guide for primary care January 2014 Evidence Contents 1 Introduction... 1 2 Detection...2 3 Risk stratification... 3 4 Treatment
More informationPHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.
PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1
More informationNew Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011
New Anticoagulants: Are we Ready to Replace Warfarin? Carole Goodine, RPh Horizon Health Network Stroke Conference 2011 Warfarin Decreases stroke risk by 60-70% Superior to ASA and ASA plus clopidogrel
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationPractical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준
Practical Management of Patients receiving Rivaroxaban 울산의대 서울아산병원 심장내과 최기준 Contents Converting to/from rivaroxaban Measuring levels of rivaroxaban Patients potentially at higher risk of bleeding Renal
More informationPrevention of thrombo - embolic complications
Update on atrial fibrillation Prevention of thrombo - embolic complications Felicita Andreotti Dept of Cardiovascular Science Catholic University, Rome, IT Consultant or speaker in past 2 years for Amgen,
More informationTA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation 1 Name of Commissioning
More informationDABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationRivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists
Rivaroxaban for the treatment of Deep Vein Thrombosis in patients unsuitable for vitamin K antagonists Traffic light classification- Amber 2 specialist initiation Information sheet for Primary Care Prescribers
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationNICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues
NICE clinical guideline 180: Atrial fibrillation Prescribing and medicines optimisation issues Andy Hutchinson Medicines Education Technical Adviser NICE Medicines and Prescribing Centre Note: this is
More informationRivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation.
South West Essex Rivaroxaban Shared Care Guideline (SCG) Rivaroxaban shared care guidelines for the prevention of stroke and embolism in adult patients with nonvalvular atrial fibrillation. Introduction
More informationNOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST
NOACS AND AF PEARLS AND PITFALLS DR LAURA YOUNG HAEMATOLOGIST NGAIRE IS 70 YEARS OLD AND IN AF. SHE HAS NO MURMURS, NORMAL BLOOD PRESSURE, EGFR OF 65ML/MIN AND NO SIGNIFICANT PAST MEDICAL HISTORY. REGARDING
More informationGuidelines for the use of existing and New Oral Anticoagulants (NOAC) in the management of Non-Valvular Atrial Fibrillation (AF)
Guidelines for the use of existing and New Oral Anticoagulants (NOAC) in the management of Non-Valvular Atrial Fibrillation (AF) July 14 Version 1 September 2012 Updated to v1.1 due to new contraindication
More informationAnticoagulation. Therapeutics. Aims. Learning Outcomes. AF Prevalence. Symptoms of AF. AF is the most common heart rhythm disturbance 1
Aims Anticoagulation K A T H E R I N E S T I R L I N G C O N S U L T A N T P H A R M A C I S T A N T I C O A G U L A T I O N A N D T H R O M B O S I S L E E D S T E A C H I N G H O S P I T A L S The aim
More informationManagement of non-valvular Atrial Fibrillation
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of non-valvular Atrial Fibrillation Guidelines for anticoagulation apply to paroxysmal, persistent and permanent AF and atrial flutter. Do
More informationWelcome to GMCCSN. Atrial Fibrillation Study Session for Anticoagulation Staff. Etrop Grange Hotel, The Coach House Tuesday 15 th May 2012
Welcome to GMCCSN Atrial Fibrillation Study Session for Anticoagulation Staff Etrop Grange Hotel, The Coach House Tuesday 15 th May 2012 Kindly sponsored by Bayer Plc & Boehringer Ingelheim Ltd Programme
More informationVersion 8, 25 April 2013
Hertfordshire Implementation of NICE TAs 249, 256 and 275 Apixaban, dabigatran and rivaroxaban, novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationNewer oral anticoagulants
Newer oral anticoagulants This bulletin principally discusses the use of the three newer oral anticoagulants licensed for use in the UK dabigatran etexilate, apixaban, and rivaroxaban for the prevention
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) The prevention of stroke and systemic embolism in atrial fibrillation (AF) with warfarin and New Oral Anticoagulants Warfarin remains the first-line option
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationBridging the Gap: How to Transition from the NOACs to Warfarin
Bridging the Gap: How to Transition from the NOACs to April 24 th 2015 UAN: 0048-0000-15-034-L01-P Amanda Styer, Pharm.D. Marion General Hospital, OhioHealth Objectives: 1. Review labeling regarding transition
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationAnti Coagulation for Stroke Prevention in Atrial Fibrillation The Case for Coumadin vs. NOACS
Anti Coagulation for Stroke Prevention in Atrial Fibrillation The Case for Coumadin vs. NOACS Cardiac Electrophysiology, Cardiology Department Meir Medical Center מודיעין על היריב ד"ר לילך דולב אחראית
More informationCommon Questions and Answers on the Practical Use of Oral Anticoagulants in Non-Valvular Atrial Fibrillation
Common Questions and Answers on the Practical Use of Oral Anticoagulants in Non-Valvular Atrial Fibrillation South West Medicines Information and Training and Regional Drug and Therapeutics Centre (Newcastle)
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationGuidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF
Guidance for prescribing of Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) and Apixaban (Eliquis ) in Patients with Non-Valvular AF Lesley Davey Staffordshire and Lancashire CSU November 2013 (Review November
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More information